Aridis Pharmaceuticals announced its participation in Key Opinion Leader, KOL, event focusing on the anti-infective treatment landscape in cystic fibrosis CF and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients. Carl Byrnes, Managing Director and Senior Research Analyst at Northland Capital Markets will host and moderate the virtual KOL. Aridis’ Chief Medical Officer Hasan Jafri, MD, and CEO Vu Truong, PhD, will also participate in the event.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARDS:
- New Approaches to Treating Infections in Cystic Fibrosis Patients – AR 501 Phase 2 Trial Update
- Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
- (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
- Aridis receives $4.85M investment from the Cystic Fibrosis Foundation
- Aridis signs deal for commercial licenses for pan-Ebola, pan-Marburg programs